Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, pegfilgrastim, docetaxel, trabectedin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
37
States / cities
Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more
Conditions
Sarcoma
Interventions
trabectedin
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
32
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 25 more
Conditions
Sarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
Conditions
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Interventions
SON-1010
Biological
Lead sponsor
Sonnet BioTherapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Sarcoma
Interventions
Trabectedin, Doxorubicin, Ifosfamide
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Santa Monica, California • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more
Conditions
Malignant Mesothelioma
Interventions
trabectedin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Conditions
Sarcoma
Interventions
trabectedin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Sarcoma
Interventions
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Trabectedin, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer
Interventions
Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ECTEINASCIDIN 743
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
42
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 34 more
Completed Phase 2 Interventional Results available

ET 743 (Yondelis) in Men With Advanced Prostate Cancer

NCT00147212
Conditions
Prostate Cancer
Interventions
ET 743
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Soft Tissue Sarcomas
Interventions
Pazopanib, Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Conditions
Sarcoma, Sarcoma Metastatic
Interventions
Olaparib, Trabectedin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Liposarcoma,Myxoid
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Coeur d'Alene, Idaho • Park Ridge, Illinois • Iowa City, Iowa + 1 more
Conditions
Dedifferentiated Liposarcoma
Interventions
RAIN-32, Trabectedin
Drug
Lead sponsor
Rain Oncology Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Palo Alto, California • Santa Monica, California • Aurora, Colorado + 16 more
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumor
Interventions
Trabectedin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Charlotte, North Carolina • Philadelphia, Pennsylvania + 1 more
Conditions
Leiomyosarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Ovarian Cancer
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 25 more
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more